RhumbLine Advisers’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History

RhumbLine Advisers’s Portfolio HARP Stock Details HARP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,724	Closed	-$86K	–	3296
2022 Q1	$86K	Buy	1,724 +228	+15%	+$11.8K	﹤0.01%	2916
2021 Q4	$113K	Hold	1,496	–	–	﹤0.01%	2927
2021 Q3	$118K	Buy	1,496 +40	+3%	+$4.02K	﹤0.01%	2978
2021 Q2	$202K	Buy	1,456 +422	+41%	+$80.5K	﹤0.01%	2922
2021 Q1	$216K	Buy	+1,034	New	+$207K	﹤0.01%	2813
2020 Q3	–	Sell	-1,016	Closed	-$169K	–	3053
2020 Q2	$169K	Buy	+1,016	New	+$158K	﹤0.01%	2830

Other funds holding HARP

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RhumbLine Advisers's HARP Position: Q2 2022 in Review

RhumbLine Advisers sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q2 2022, closing a stake of 1,724 shares — an estimated $86K sold.

RhumbLine Advisers first reported a position in HARP in Q2 2020 and held it in 6 quarters. The position peaked at $216K in Q1 2021. 63 funds tracked by Wall St. Rank hold HARP as of Q2 2022.

RhumbLine Advisers reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
RhumbLine Advisers sold 1,724 Harpoon Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $86K.
RhumbLine Advisers first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q2 2020 and held it in 6 quarters.
RhumbLine Advisers's Harpoon Therapeutics, Inc. Common Stock position peaked at $216K in Q1 2021.
63 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q2 2022.

Based on RhumbLine Advisers's 13F filing for Q2 2022, filed 11 Aug 2022.